Brief: Hcw Biologics Reports Q1 C2023 Financial Results And Recent Business Highlights

Hcw Biologics

09/05/2023 13:37

May 9 (Reuters) - HCW Biologics Inc  HCWB.O :
    * HCW BIOLOGICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
RECENT BUSINESS HIGHLIGHTS
    * HCW BIOLOGICS INC - CASH AND CASH EQUIVALENTS, SHORT-TERM
INVESTMENTS AND PROCEEDS OF DEVELOPMENT LINE OF CREDIT EXTENDS
CO'S CASH RUNWAY INTO 2025
    * HCW BIOLOGICS - ON APRIL 27, IN ALTOR/NANTCELL MATTER,
U.S.
COURT APPROVED PARTIES' STIPULATION & ORDERED PARTIES TO
ARBITRATION
    * HCW BIOLOGICS INC - ON MAY 1, ALTOR/NANTCELL FILED DEMAND
AGAINST CO BEFORE JAMS
    * HCW BIOLOGICS -ON MAY 3, ALTOR/NANTCELL DISMISSED FEDERAL
COURT
ACTION WITHOUT PREJUDICE, COURT ORDERED CASE DISMISSED WITHOUT
PREJUDICE, CLOSED CASE
    * HCW BIOLOGICS INC - ALTOR/NANTCELL'S PROCEEDING AGAINST CO
WILL
NOW PROCEED IN ARBITRATION BEFORE JAMS
    * HCW BIOLOGICS - IN YEAR AHEAD, SEES TO INCUR LEGAL
EXPENSES ON
OWN BEHALF IN CONNECTION WITH LEGAL PROCEEDINGS BROUGHT AGAINST
IT BY ALTOR/NANTCELL

Source text for Eikon:  ID:nGNX757S1b 
Further company coverage:  HCWB.O 

 ((Reuters.Briefs@thomsonreuters.com;))